SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: celeryroot.com who wrote (13917)1/30/1998 8:02:00 AM
From: tonyt  Read Replies (1) | Respond to of 32384
 
Not really, since it has diabetes applications and partnerhips with Lily (among other big names), this could be (or already is) a competitor of Ligand.



To: celeryroot.com who wrote (13917)1/30/1998 9:34:00 AM
From: Henry Niman  Respond to of 32384
 
Celeryroot, I think that Inhale's competition with LLY (or any other company that relies on injected drugs), would be a major plus for LGND, because it would put more pressure on the partner to push development of LGND's oral compounds.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News